On November 11, Oklo Inc. saw an Intraday Rise of 4.53% in Regular Trading, with the stock trading at $26.0124 and turnover reaching $23.8289 million.
The move was supported by the company’s announcement that the U.S. Department of Energy cleared the final operating hold point for the Groves-1 isotope test reactor, allowing unrestricted operations and entry into its research, testing and training phase.
Groves-1 had reached first criticality in August under the DOE Reactor Pilot Program. The company said operating experience from the reactor will directly inform Groves-2 Forge, its planned isotope production and processing pilot facility initially targeting lutetium-177 for cancer treatments. The latest regulatory milestone adds to recent investor support from better-than-expected quarterly results, including revenue of $1.9 million versus expectations of $1.0 million, a loss per share of $0.22 versus an expected loss of $0.27, and cash, equivalents and marketable securities of $3.13 billion.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments